KANO
Live / Applied — Fourth extension granted (statement of use) (as of 12 Mar 2026)
What this means for you
Not registered yet, but its 01 Dec 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97700230
- Mark type
- Stylized text
- Filed
- 01 Dec 2022
- Published for opposition
- 23 Jan 2024
- Attorney of record
- Rocky Cislak
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for single-stranded DNA; Biologics, namely, nucleic acids for use as therapeutics for clinical and medical use
- Class 040 — Treatment of materials: Custom manufacturing of nucleic acids for diagnostic, medical and commercial applications in relation to cell and gene therapies; Custom manufacturing of nucleic acids, biological organisms and components and products thereof in the nature of therapeutics for pharmaceutical drug development; Manufacturing services for others, namely, manufacture of synthetic DNA and genes; Custom manufacturing, namely, synthesis of pharmaceuticals
- Class 042 — Scientific and technological services: Pharmaceutical drug development services; Scientific research and development of synthesis of pharmaceuticals; Scientific research and development; Pharmaceutical, medical, scientific, and biopharmaceutical research and development; Biochemical research and development services, namely, custom development and synthesis of nucleic acids, biological organisms, and components and products thereof for pharmaceutical drug development; Design and development in the field of custom synthesis of cells and vectors for diagnostic, medical and commercial applications in relation to the design of nucleic acids and genetic medicines; Bioinformatic design of genetically engineered organisms; Research, design, and development of genetically engineered organisms; Product development consultation in the fields of pharmaceutical, medical, scientific, and biopharmaceutical research and development; Product development in the fields of products for pharmaceutical drug development; Research and development in the field of pharmaceuticals; Research and design services relating to pharmaceuticals; Research in the field of pharmaceutical preparations
Owner
- Kano Therapeutics Inc., Cambridge, MA, US
- Kano Therapeutics Inc., Cambridge, MA, US
Prosecution history
- 11 Sept 2026 — SOU TEAS EXTENSION RECEIVED
- 13 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Mar 2026 — SOU EXTENSION 4 GRANTED
- 12 Mar 2026 — SOU EXTENSION 4 FILED
- 12 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 16 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 15 Sept 2025 — SOU EXTENSION 3 GRANTED
- 15 Sept 2025 — SOU EXTENSION 3 FILED
- 15 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 20 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 Mar 2025 — SOU EXTENSION 2 GRANTED
- 19 Mar 2025 — SOU EXTENSION 2 FILED
- 19 Mar 2025 — SOU TEAS EXTENSION RECEIVED
- 16 Sept 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 16 Sept 2024 — SOU EXTENSION 1 GRANTED